CoChat
Sign Up
Cited by 351Heart Failure Treatment and ManagementHeart rate and cardiovascular healthCardiovascular and exercise physiology

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Clinical Implications of the New York Heart Association Classification

Open access
Caraballo, César, Desai, Nihar R., Mulder, Hillary, Alhanti, Brooke, Wilson, F. Perry, Fiuzat, Mona, Felker, G. Michael, Piña, Ileana L., O'Connor, Christopher M., Lindenfeld, Joanne, Januzzi, James L., Cohen, Lawrence S., Ahmad, Tariq·2019·Journal of the American Heart Association
DOI 10.1161/jaha.119.014240PMC PMC6912957
Open this paper in CoChat — free accountOpen PDF

Abstract

Background The New York Heart Association ( NYHA ) classification has served as a fundamental tool for risk stratification of heart failure ( HF ) and determines clinical trial eligibility and candidacy for drugs and devices. However, its ability to adequately stratify risk is unclear. Methods and Results To compare NYHA class with objective assessments and survival in patients with HF , we performed secondary analyses of 4 multicenter National Institutes of Health–funded HF clinical trials that included patients classified as NYHA class II or III: TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist), DIG (The Effect of Digoxin on Mortality and Morbidity in Patients With Heart Failure), HF‐ACTION (Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure), and GUIDE‐IT (Guiding Evidence‐Based Therapy Using Biomarker Intensified Treatment in Heart Failure). Twenty‐month cumulative survival was compared between classes using Kaplan–Meier curves and the log rank test. NT ‐proBNP (N‐terminal pro–B‐type natriuretic peptide), Kansas City Cardiomyopathy Questionnaire ( KCCQ ) scores, 6‐minute walk distances, left ventricular ejection fraction, and cardiopulmonary test parameters were compared using Wilcoxon rank sum tests and percentage overlap using kernel density estimations. Cumulative mortality varied significantly across NYHA classes and HF clinical trials (likelihood ratio, P <0.001). Mortality at 20 months for NYHA class II ranged from 7% for patients in HF ‐ ACTION to 15% in GUIDE ‐ IT , whereas mortality for NYHA class III ranged from 12% in TOPCAT to 26% in GUIDE ‐ IT . There was substantial percentage overlap in values for NT ‐pro BNP levels (79% and 69%), KCCQ scores (63% and 54%), 6‐minute walk distances (63% and 54%), and left ventricular ejection fraction (88% and 83%). Similarly, there was substantial overall in values for minute ventilation–carbon dioxide production relationship (71%), maximal oxygen uptake (54%), and exercise duration (53%). Conclusions The NYHA system poorly discriminates HF patients across the spectrum of functional impairment. These findings raise important questions about the need for improved phenotyping of these patients to facilitate risk stratification and response to interventions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.119.014240

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Kaplan–Meier curves for all‐cause mortality according to clinical trial and New York Heart Association (NYHA) classification. Clinical trials shown are TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), DIG (The Effect of Digoxin on Mortality and Morbidity in Patients With Heart Failure), HF‐ACTION (Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure), and GUIDE‐IT (Guiding Evidence‐Based Therapy Using Biomarker Intensified Treatment in Heart Failure).
Figure 1 Kaplan–Meier curves for all‐cause mortality according to clinical trial and New York Heart Association (NYHA) classification. Clinical trials shown are TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), DIG (The Effect of Digoxin on Mortality and Morbidity in Patients With Heart Failure), HF‐ACTION (Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure), and GUIDE‐IT (Guiding Evidence‐Based Therapy Using Biomarker Intensified Treatment in Heart Failure).CC BY-NC · PubMed Central
Figure 2 Distributions of objective measures of heart failure according New York Heart Association (NYHA) classes II and III (red shows overlap in values). Numbers of patients classified as NYHA classes II and III, respectively, were as follows: GUIDE‐IT, n=447 and n=358); HF‐ACTION, n=1477 and n=831. Values represent medians and interquartile ranges between NYHA classes II and III in GUIDE‐IT and HF‐ACTION clinical trials. A, Kansas City Cardiomyopathy Questionnaire (KCCQ) distributions. B, Six‐minute walk distance distributions. C, NT‐proBNP (N‐terminal pro–B‐type natriuretic peptide) distributions. D, Left ventricular ejection fraction (LVEF) distributions. GUIDE‐IT indicates Guiding Evidence‐Based Therapy Using Biomarker Intensified Treatment in Heart Failure; HF‐ACTION, Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure; Q, quartile.
Figure 2 Distributions of objective measures of heart failure according New York Heart Association (NYHA) classes II and III (red shows overlap in values). Numbers of patients classified as NYHA classes II and III, respectively, were as follows: GUIDE‐IT, n=447 and n=358); HF‐ACTION, n=1477 and n=831. Values represent medians and interquartile ranges between NYHA classes II and III in GUIDE‐IT and HF‐ACTION clinical trials. A, Kansas City Cardiomyopathy Questionnaire (KCCQ) distributions. B, Six‐minute walk distance distributions. C, NT‐proBNP (N‐terminal pro–B‐type natriuretic peptide) distributions. D, Left ventricular ejection fraction (LVEF) distributions. GUIDE‐IT indicates Guiding Evidence‐Based Therapy Using Biomarker Intensified Treatment in Heart Failure; HF‐ACTION, Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure; Q, quartile.CC BY-NC · PubMed Central
Figure 3 Distributions of cardiopulmonary exercise testing variables according New York Heart Association (NYHA) classes II and III in HF‐ACTION (red shows overlap in values). Values in figure represent medians and interquartile ranges. A, Ventilation–carbon dioxide production relationship (VE/vco 2 slope). B, Cardiopulmonary exercise testing (CPX) duration. C, Maximal oxygen uptake (peak vo 2). HF‐ACTION indicates Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure; Q, quartile.
Figure 3 Distributions of cardiopulmonary exercise testing variables according New York Heart Association (NYHA) classes II and III in HF‐ACTION (red shows overlap in values). Values in figure represent medians and interquartile ranges. A, Ventilation–carbon dioxide production relationship (VE/vco 2 slope). B, Cardiopulmonary exercise testing (CPX) duration. C, Maximal oxygen uptake (peak vo 2). HF‐ACTION indicates Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure; Q, quartile.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

Sorted by citations

See all 351

Related

Metadata

Authors
Caraballo, C., Desai, N. R., Mulder, H., Alhanti, B., Wilson, F. P., Fiuzat, M., Felker, G. M., Piña, I. L., O'Connor, C. M., Lindenfeld, J., Januzzi, J. L., Cohen, L. S., & Ahmad, T.
Affiliations
  • Yale University (US)
  • Duke Clinical Research Institute (US)
  • Detroit Medical Center (US)
  • Inova Heart and Vascular Institute Fairfax VA
  • Vanderbilt University Medical Center (US)
  • Massachusetts General Hospital (US)
Corresponding author
Ahmad, Tariq
ORCID
Venue
Journal of the American Heart Association
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2019-12-03
Volume
8
Issue
23
Pages
e014240-e014240
ISSN
2047-9980 (ISSN-L)
DOI
10.1161/jaha.119.014240
PMC
PMC6912957
OpenAlex
W2991004728
Cited by
351
References
14
Citations by year
2026: 48 · 2025: 76 · 2024: 65 · 2023: 74 · 2022: 43 · 2021: 34 · 2020: 10
FWCI
15.73
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Journal of the American Heart Association (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institutes of Health (UL1TR001863)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079310)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
Keywords
NYHA functional class, heart failure, risk stratification, mortality, NT-proBNP, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, left ventricular ejection fraction, exercise capacity, patient phenotyping, TOPCAT, dig
MeSH terms
Heart Failure, Humans, New York, Societies, Medical, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review